Holen Sie sich die Stockscreener-App
14.85
1.02%
0.17
Schlusskurs vom Vortag:
$14.68
Offen:
$14.66
24-Stunden-Volumen:
408.89K
Relative Volume:
1.16
Marktkapitalisierung:
$462.99M
Einnahmen:
$322.67M
Nettoeinkommen (Verlust:
$-61.63M
KGV:
-7.5557
EPS:
-1.9654
Netto-Cashflow:
$-124.21M
1W Leistung:
+1.37%
1M Leistung:
-36.71%
6M Leistung:
-32.22%
1J Leistung:
-12.66%
1-Tages-Spanne:
$14.66
$15.05
1-Wochen-Bereich:
$14.15
$15.26
52-Wochen-Spanne:
$13.46
$31.04
Fulgent Genetics Inc Stock (FLGT) Company Profile
Firmenname
Fulgent Genetics Inc
Sektor
Branche
Telefon
626-350-0537
Adresse
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FLGT
Fulgent Genetics Inc
|
14.82 | 458.47M | 322.67M | -61.63M | -124.21M | -1.9654 |
|
TMO
Thermo Fisher Scientific Inc
|
469.60 | 176.79B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
187.21 | 131.71B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
571.02 | 45.48B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.41 | 31.55B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
284.54 | 27.79B | 3.17B | 642.63M | 516.49M | 10.77 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Hochstufung | UBS | Neutral → Buy |
| 2023-12-07 | Eingeleitet | UBS | Neutral |
| 2022-12-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-11-18 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Underperform |
| 2021-01-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2020-11-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-08-20 | Eingeleitet | Oppenheimer | Outperform |
| 2020-05-29 | Eingeleitet | BTIG Research | Buy |
| 2019-11-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-03-01 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-11-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Fulgent Genetics Inc Aktie (FLGT) Neueste Nachrichten
Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm - The Globe and Mail
Fulgent Genetics: A Major Market Misconception (NASDAQ:FLGT) - Seeking Alpha
Fulgent Genetics (FLGT) Earnings Transcript - AOL.com
Aug Sectors: Should I hold or sell Fulgent Genetics Inc now2026 Review & Precise Entry and Exit Recommendations - baoquankhu1.vn
Fulgent Genetics Hits New 52-Week Low at $14.01 Amid Declining Performance - Markets Mojo
Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Wall Street Zen - MarketBeat
Technical Analysis: Is Fulgent Genetics Inc a top pick in the sectorQuarterly Earnings Report & AI Powered Trade Plan Recommendations - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.FLGT - PR Newswire
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of "Hold" by Brokerages - MarketBeat
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.FLGT - FinancialContent
FLGT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fulgent Genetics (FLGT) CSO has shares withheld to cover RSU taxes - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) CEO has shares withheld for taxes - Stock Titan
Fulgent Genetics (FLGT) Is Down 33.4% After 2025 Results And Oncology-Focused ExpansionWhat's Changed - Yahoo Finance
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach - GlobeNewswire
UBS Adjusts Fulgent Genetics Price Target to $22 From $35, Maintains Buy Rating - marketscreener.com
Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results - marketscreener.com
Assessing Fulgent Genetics (FLGT) Valuation After Earnings Outperformance And AI Oncology Pipeline Progress - simplywall.st
A Look At Fulgent Genetics (FLGT) Valuation After 2025 Results And 2026 Revenue Guidance - Yahoo Finance
Fulgent Genetics (NASDAQ:FLGT) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Fulgent Genetics (FLGT) Loss Widening In Q4 2025 Tests Bullish Growth Narratives - simplywall.st
Fulgent Q4 2025 slides: EPS beats, but customer loss drives stock plunge - Investing.com Australia
Fulgent Genetics (FLGT) Reports Strong Q4 Revenue Growth - GuruFocus
Fulgent Genetics (NASDAQ:FLGT) Issues FY 2026 Earnings Guidance - MarketBeat
Fulgent Genetics Inc (FLGT) Q4 2025 Earnings Call Highlights: Na - GuruFocus
Fulgent Genetics Q4 Earnings Call Highlights - MarketBeat
Fulgent Genetics (FLGT) Reports Strong Q4 Earnings Despite Reven - GuruFocus
Earnings call transcript: Fulgent Genetics Q4 2025 beats EPS estimates, stock tumbles - Investing.com
Fulgent Genetics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Fulgent Genetics earnings beat by $0.22, revenue fell short of estimates - Investing.com Canada
Fulgent Genetics, Inc. (FLGT) Q4 Earnings Top Estimates - Yahoo Finance
Fulgent Genetics Posts 2025 Results and 2026 Outlook - TipRanks
Fulgent Genetics (FLGT) Reports Q4 Revenue Below Expectations - GuruFocus
FLGT Projects FY26 Revenue and Financial Outlook - GuruFocus
Fulgent Genetics Q4 Non-GAAP Net Income, Revenue Rise; 2026 Guidance Set -- Shares Down Pre-Bell - marketscreener.com
(FLGT) Fulgent Genetics Expects 2026 Revenue About $350M, vs. FactSet Est of $356.3M - marketscreener.com
(FLGT) Fulgent Expects 2026 Adjusted Loss About $1.45 a Share, vs. FactSet Est of $0.32 Loss - marketscreener.com
FULGENT GENETICS ($FLGT) Releases Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (FLGT) Fulgent Genetics Posts Q4 Revenue $83.3M, vs. FactSet Est of $85.4M - marketscreener.com
Earnings Flash (FLGT) Fulgent Genetics Posts Q4 Adjusted EPS $0.16, vs. FactSet Est of $0.03 - marketscreener.com
Fulgent Genetics, Inc. SEC 10-K Report - TradingView
Fulgent Genetics Q4 revenue misses; forecasts about $350 mln in 2026 revenue - TradingView
Fulgent Genetics Q4 Earnings Assessment - Benzinga
BRIEF-Fulgent Genetics Q4 Revenue USD 83.336 Million - TradingView
Earnings Preview: Fulgent Genetics - Benzinga
Fulgent Genetics and Azenta Compared as Investments - National Today
Fulgent Genetics (FLGT) CEO receives stock awards and tax share withholding - Stock Titan
Fulgent Genetics (FLGT) COO receives stock awards and tax withholdings - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) CFO gets equity awards, covers taxes - Stock Titan
ETF Watch: How liquid is Fulgent Genetics Inc stockQuarterly Market Review & Technical Entry and Exit Alerts - baoquankhu1.vn
Finanzdaten der Fulgent Genetics Inc-Aktie (FLGT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):